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jGSK Vaccines S.r.l., Siena, ItalyThe authors regret that since the publication of this paper, they have discovered an error in the Conclusion of the Abstract. The corrected
Conclusion is listed below. The authors would also like to correct the name of Dr. Miguel Tortajada-Girbés in The European Men B vaccine
study group section.
Conclusion: Waning of protective antibodies occurred 24–36 months after toddler booster regardless of age at boost. This was least
marked against target strains 5/99 and M10713. A robust memory response occurred after a booster dose given at 4 years of age.
The authors would like to apologise for any inconvenience caused.
